Diadema Partners LP Pyxis Oncology, Inc. Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
A detailed history of Diadema Partners LP transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 150,000 shares of PYXS stock, worth $676,500. This represents 0.09% of its overall portfolio holdings.
Number of Shares
150,000Holding current value
$676,500% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
74Shares Held
22.6MCall Options Held
21.5KPut Options Held
0-
Laurion Capital Management LP New York, NY3.63MShares$16.4 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$12.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.5MShares$11.3 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.16MShares$9.76 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.18MShares$5.31 Million0.01% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $158M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...